Truist initiates NewAmsterdam Pharma stock coverage with buy rating

Truist initiated coverage on NewAmsterdam Pharma (NAMS) with a Buy and $57 price target, implying ~94% upside from the current $29.44 and modeling $2.8bn peak adjusted sales for the pipeline. Cantor Fitzgerald reiterated Overweight ($49 PT), Guggenheim raised its PT to $45 from $41 citing an accelerated EU launch likely in 2027 (vs prior 2029), and Leerink raised its PT to $55, reflecting broad analyst optimism. A European regulatory decision for obicetrapib + ezetimibe is expected in H2 2026 and the PREVAIL cardiovascular outcomes trial is progressing, supporting upside while approval and commercial launch risks remain.

Analysis

Obicetrapib’s oral profile creates a structurally different commercialization path vs injectable PCSK9s/siRNAs: faster patient uptake in outpatient primary-care settings but much greater sensitivity to formulary placement and net price. To justify a $~3bn peak revenue outcome requires low-single-digit penetration of high-risk statin-treated pools or ~2–3m treated patients at a net price in the $1k–$1.5k/year band — anything materially lower on price or share makes consensus revenue assumptions hard to hit. The real battleground will be guideline committees and payers over 12–36 months; an early EU approval can create physician awareness but won’t force adoption without favorable reimbursement and compelling subgroup CV outcomes data.

Key binary risks are asymmetric and multi-year: an adverse PREVAIL signal or even a modestly underwhelming CV relative-risk reduction will compress upside far more than it reduces downside, because uptake depends on hard outcomes for payers. Conversely, a clean CVOT plus class-leading Lp(a)/diabetes subgroup data would justify premium placement and create M&A optionality; expect mid-to-large pharma interest within 12 months of robust outcomes. Short-term noise will center on regulatory wording and label scope — expect 10–30% intramonth swings around these releases.

Market consensus appears to price a favorable regulatory pathway and a quick commercial ramp; that may be underdone on execution complexity (payer contracts, guideline lag) but potentially overdone on timeline. Positioning should capture the convexity of a positive regulatory run while protecting against the binary CVOT tail: structured option exposure or collars are preferable to outright equity leverage until post‑approval commercial evidence is visible.

Key Decisions for Investors

• NAMS — buy asymmetric LEAP call spread (18–30 month): long near‑ATM Jan‑2028 calls + sell higher strike ~100–150% above ATM to fund. Rationale: captures EU regulatory/debut upside with capped cost; payoff 3–6x on approval + early uptake, max loss = premium (small % of portfolio).
• NAMS — core long with downside protection (12–36 month): buy shares and buy a 9–12 month put ~20–25% OTM (or construct a collar). Rationale: participates in guideline/payer wins while limiting binary CVOT/regulatory tail; target risk/reward ~2:1 upside to protected downside for medium conviction sizing.
• NAMS / NVS pair — directional capture of oral convenience premium (12–36 month): long NAMS (smaller size) paired with a modest short position in NVS (or other PCSK9/siRNA incumbent) to express share rotation. Rationale: if obicetrapib wins primary-care share, relative re-rating likely; risk: incumbents have diversified revenue so keep pair ratio small and hedge overall biotech exposure.
• Event hedge — buy short-dated puts into key regulatory windows (weeks–months): size as insurance (1–3% portfolio) to protect against headline-driven selloffs around regulatory wording or interim PREVAIL readouts. Rationale: protects against >30% downside from negative headlines at low carry cost.